Nuke, based on the lack of significant revenue in Canada, and the tone of their comments on the Pfizer agreement, it seems that selling Vascepa has been a bit of an afterthought for Pfizer Canada (Pfizer accounts for about half of the $1.5M per month in revenue, so maybe $10M a year). It looks like they re-structured the new agreement with Pfizer to reduce the salesforce going forward. Initially, Pfizer agreed to do this to avoid laying off salespeople in Canada and keep them working.
It will be great to see growth continue. But it's also important that Pfizer have good feedback from docs regarding their patients on Vascepa.
News 
Market Data 
Discover 
